Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. This work represents a key milestone in the company’s chemistry, manufacturing and controls (CMC) strategy as it advances toward IND-enabling studies and planning for first-in-human clinical evaluation.
The program will focus on optimizing synthetic processes, improving yield and reproducibility, and scaling production of key intermediates required for downstream manufacturing and formulation. The effort will be conducted in collaboration with Dalton Pharma Services and is intended to establish a robust, scalable manufacturing process capable of supporting continued preclinical development, regulatory readiness and future clinical supply requirements. For more details, see the full press release at https://nnw.fm/kfFWv.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. More information is available at https://oncoinnovations.com/.
This announcement is significant because advancing manufacturing process development is a critical step in bringing a drug candidate from preclinical research to clinical trials. By establishing a scalable and reproducible manufacturing process, Onco-Innovations is laying the groundwork for regulatory submissions and eventual commercialization. The collaboration with Dalton Pharma Services, a contract development and manufacturing organization, provides the expertise needed to navigate the complexities of pharmaceutical manufacturing.
The development of ONC010 targets solid tumours, addressing a significant unmet medical need. Solid tumours account for the majority of cancer cases, and innovative therapies are urgently required. If successful, ONC010 could offer a new treatment option for patients. The progress in CMC activities also signals to investors that Onco-Innovations is moving closer to clinical milestones, which could enhance the company’s valuation and attract further partnership opportunities.
In summary, the initiation of process development and scale-up for ONC010 is a crucial step in the drug development pipeline. It demonstrates Onco-Innovations’ commitment to advancing its oncology pipeline and preparing for future clinical trials. The company’s focus on robust manufacturing processes is essential for regulatory approval and eventual patient access.
